MS, MMSc, PA-C
Associate Chief of Education, Winship Cancer Institute of Emory University
Optimizing Bone Protection in Multiple Myeloma
In multiple myeloma (MM), bone disease is a major source of morbidity, making bone-protective agents like zoledronic acid (ZOL) and denosumab essential to care....
Early Daratumumab Monotherapy Delays Progression in High-Risk Smoldering Myeloma
Researchers of the phase 3 Aquila study presented at the 66th ASH Annual Meeting and showed that daratumumab (D) monotherapy significantly delays progression in patients with high-risk smoldering multiple myeloma...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Cilta-cel Enhances Quality of Life and Delays Symptoms in Refractory Myeloma
Researchers of a phase 3 trial evaluated patient-reported outcomes from the CARTITUDE-4 study, comparing ciltacabtagene autoleucel (cilta-cel) with standard-of-care regimens in patients with lenalidomide-refractory multiple myeloma....
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Interconnected Burdens: Fatigue, Sleep, Mood, and Function in Newly Diagnosed Multiple Myeloma
Patients newly diagnosed with multiple myeloma (MM) often present with anemia, fatigue, sleep disturbances, pain, and mood disruption—all of which impact quality of life and functional performance....
Frailty Assessments in Personalized Treatment for Older Adults with Multiple Myeloma: A Case Study
Authors of this article discuss the role of frailty assessments in managing older adults with multiple myeloma (MM). Frailty scores, including the IMWG score, are valuable tools for predicting treatment...
Dupilumab Effectively Manages Lenalidomide-Induced Rash in Patients With Multiple Myeloma
Lenalidomide (Len) is a crucial treatment for multiple myeloma (MM), improving progression-free survival (PFS), but it often causes a rash that leads to dose reductions or interruptions. Len rash occurs...
